Inocras, a bioinformatics-led startup harnessing the power of whole-genome data and proprietary AI analytics to deliver curated insights for oncology and rare cancer diseases, has raised $31 million in an oversubscribed Series B-3 financing.
Including the Series B-3 round, Inocras has raised approximately $100 million in equity funding to date.
The Series B-3 investment round was led by NDS Corporation, Aimed Bio Inc, IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities, Shinhan Securities, DSC Investment, Dunamu & Partners, and InterVest.
The financing follows continued clinical and scientific validation of Inocras’s whole-genome approach. Through its collaboration with researchers at the Broad Institute, Inocras recently analyzed whole-genome data from The Cancer Genome Atlas across thousands of cancer cases, demonstrating the utility of standardized whole-genome analysis at scale and informing broader use of comprehensive genomic information in oncology.
Inocras has already established a record of real-world clinical adoption across Asia, with its whole-genome sequencing solutions currently used by more than 100 cancer institutions and in thousands of patient cases. The company has also established a significant commercial presence in Hong Kong and is supporting approximately thirty hospitals in South Korea.
“We have already seen meaningful adoption across cancer institutions in Asia, where our technology has been used in thousands of patient cases,” said Jehee Suh, CEO of Inocras.
CEO Jehee Suh said: “Our next objective is to bring that clinical experience to the United States and help make whole-genome analysis a standard part of cancer care. This financing gives us the resources to expand our clinical presence, support adoption within hospitals, and build the evidence and infrastructure required to achieve that goal.”